Tezosentan in patients with acute heart failure : Design of the value of endothelin receptor inhibition with tezosentan in acute heart failure study (VERITAS)
Identifieur interne : 004346 ( PascalFrancis/Checkpoint ); précédent : 004345; suivant : 004347Tezosentan in patients with acute heart failure : Design of the value of endothelin receptor inhibition with tezosentan in acute heart failure study (VERITAS)
Auteurs : John R. Teerlink [États-Unis] ; John J. V. Mcmurray [Royaume-Uni] ; Robert C. Bourge [États-Unis] ; John G. F. Cleland [Royaume-Uni] ; Gadi Cotter [États-Unis] ; Guillaume Jondeau [France] ; Henry Krum [Australie] ; Marco Metra [Italie] ; Christopher M. O'Connor [États-Unis] ; John D. Parker [Canada] ; Guillermo Torre-Amione [États-Unis] ; Dirk J. Van Veldhuisen [Pays-Bas] ; Aline Frey [Suisse] ; Maurizio Rainisio [Suisse] ; Isaac Kobrin [Suisse]Source :
- The American heart journal [ 0002-8703 ] ; 2005.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Background Endothelin 1 is a potent endogenous vasoconstrictor neurohormone, and endothelin 1 plasma concentrations predict adverse outcomes in patients with acute heart failure (AHF). Tezosentan, an intravenous endothelin receptor antagonist, improved hemodynamics in patients with AHF; however, its effects on morbidity and mortality have not been evaluated. Methods The VERITAS program consists of 2 identical, double-blind, randomized, placebo-controlled, concurrently conducted trials (VERITAS-1 and VERITAS-2), performed in 150 centers in Europe, Israel, Australia, and North America. The program is designed to enroll at least 1760 patients hospitalized with dyspnea at rest because of AHF requiring intravenous therapy. In addition to conventional therapy, patients are randomized to receive tezosentan (5 mg/h for 30 minutes, then 1 mg/h for 24-72 hours) or matching placebo. The 2 prespecified primary end points are the incidence of death or worsening heart failure at 7 days in the combined studies and the change from baseline in dyspnea over the first 24 hours of treatment, measured using a visual analog scale in VERITAS-1 and VERITAS-2, individually. Results Enrollment started in April 2003, and the program was discontinued in November 2005 because of the low probability of achieving a significant treatment effect. Conclusions No currently available agents have been shown in a prospective, randomized, clinical trial to improve outcomes in patients with AHF. Thus, the VERITAS program will provide valuable insights into the effect of tezosentan on clinical outcomes in patients with AHF, as well as hemodynamics and clinical symptoms.
Affiliations:
- Australie, Canada, France, Italie, Pays-Bas, Royaume-Uni, Suisse, États-Unis
- Californie, Groningue (province), Texas, Écosse
- Glasgow, Groningue, Houston, San Francisco
- Baylor College of Medicine, Université de Glasgow
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:05-0391874Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Tezosentan in patients with acute heart failure : Design of the value of endothelin receptor inhibition with tezosentan in acute heart failure study (VERITAS)</title><author><name sortKey="Teerlink, John R" sort="Teerlink, John R" uniqKey="Teerlink J" first="John R." last="Teerlink">John R. Teerlink</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Section of Cardiology, San Francisco Veterans Affairs Medical Center and University of California, San Francisco</s1><s2>San Francisco, Calif</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Medicine and Therapeutics, University of Glasgow</s1><s2>Glasgow</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université de Glasgow</orgName></affiliation></author><author><name sortKey="Bourge, Robert C" sort="Bourge, Robert C" uniqKey="Bourge R" first="Robert C." last="Bourge">Robert C. Bourge</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicine, University of Alabama at Birmingham</s1><s2>Birmingham, Ala</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Birmingham, Ala</wicri:noRegion></affiliation></author><author><name sortKey="Cleland, John G F" sort="Cleland, John G F" uniqKey="Cleland J" first="John G. F." last="Cleland">John G. F. Cleland</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Cardiology, Castlehill Hospital, University of Hull, Kingston upon Hull</s1><s3>GBR</s3><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Department of Cardiology, Castlehill Hospital, University of Hull, Kingston upon Hull</wicri:noRegion></affiliation></author><author><name sortKey="Cotter, Gadi" sort="Cotter, Gadi" uniqKey="Cotter G" first="Gadi" last="Cotter">Gadi Cotter</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Departmentof Medicine, Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Durham, NC</wicri:noRegion></affiliation></author><author><name sortKey="Jondeau, Guillaume" sort="Jondeau, Guillaume" uniqKey="Jondeau G" first="Guillaume" last="Jondeau">Guillaume Jondeau</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Cardiology, Hôpital Ambroise Paré</s1><s2>Boulogne</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Boulogne</wicri:noRegion><wicri:noRegion>Hôpital Ambroise Paré</wicri:noRegion><wicri:noRegion>Boulogne</wicri:noRegion></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Departments of Medicine, Epidemiology and Preventive Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>7 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Melbourne, Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Metra, Marco" sort="Metra, Marco" uniqKey="Metra M" first="Marco" last="Metra">Marco Metra</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Cardiology, University of Brescia</s1><s2>Brescia</s2><s3>ITA</s3><sZ>8 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Brescia</wicri:noRegion></affiliation></author><author><name sortKey="O Connor, Christopher M" sort="O Connor, Christopher M" uniqKey="O Connor C" first="Christopher M." last="O'Connor">Christopher M. O'Connor</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Departmentof Medicine, Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Durham, NC</wicri:noRegion></affiliation></author><author><name sortKey="Parker, John D" sort="Parker, John D" uniqKey="Parker J" first="John D." last="Parker">John D. Parker</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Mount Sinai and United Health Network Hospitals</s1><s2>Toronto</s2><s3>CAN</s3><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Mount Sinai and United Health Network Hospitals</wicri:noRegion></affiliation></author><author><name sortKey="Torre Amione, Guillermo" sort="Torre Amione, Guillermo" uniqKey="Torre Amione G" first="Guillermo" last="Torre-Amione">Guillermo Torre-Amione</name><affiliation wicri:level="4"><inist:fA14 i1="10"><s1>Methodist DeBakey Heart Center, The Winter's Center for Heart Failure Research, Baylor College of Medicine</s1><s2>Houston, Tex</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Cardiology, Thorax Center, University Hospital Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>12 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Frey, Aline" sort="Frey, Aline" uniqKey="Frey A" first="Aline" last="Frey">Aline Frey</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Actelion Pharmaceuticals, Ltd</s1><s2>Allschwil</s2><s3>CHE</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Allschwil</wicri:noRegion></affiliation></author><author><name sortKey="Rainisio, Maurizio" sort="Rainisio, Maurizio" uniqKey="Rainisio M" first="Maurizio" last="Rainisio">Maurizio Rainisio</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Actelion Pharmaceuticals, Ltd</s1><s2>Allschwil</s2><s3>CHE</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Allschwil</wicri:noRegion></affiliation></author><author><name sortKey="Kobrin, Isaac" sort="Kobrin, Isaac" uniqKey="Kobrin I" first="Isaac" last="Kobrin">Isaac Kobrin</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Actelion Pharmaceuticals, Ltd</s1><s2>Allschwil</s2><s3>CHE</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Allschwil</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0391874</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0391874 INIST</idno><idno type="RBID">Pascal:05-0391874</idno><idno type="wicri:Area/PascalFrancis/Corpus">004790</idno><idno type="wicri:Area/PascalFrancis/Curation">001913</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">004346</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004346</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Tezosentan in patients with acute heart failure : Design of the value of endothelin receptor inhibition with tezosentan in acute heart failure study (VERITAS)</title><author><name sortKey="Teerlink, John R" sort="Teerlink, John R" uniqKey="Teerlink J" first="John R." last="Teerlink">John R. Teerlink</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Section of Cardiology, San Francisco Veterans Affairs Medical Center and University of California, San Francisco</s1><s2>San Francisco, Calif</s2><s3>USA</s3><sZ>1 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">San Francisco</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Medicine and Therapeutics, University of Glasgow</s1><s2>Glasgow</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName><orgName type="university">Université de Glasgow</orgName></affiliation></author><author><name sortKey="Bourge, Robert C" sort="Bourge, Robert C" uniqKey="Bourge R" first="Robert C." last="Bourge">Robert C. Bourge</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medicine, University of Alabama at Birmingham</s1><s2>Birmingham, Ala</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Birmingham, Ala</wicri:noRegion></affiliation></author><author><name sortKey="Cleland, John G F" sort="Cleland, John G F" uniqKey="Cleland J" first="John G. F." last="Cleland">John G. F. Cleland</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Cardiology, Castlehill Hospital, University of Hull, Kingston upon Hull</s1><s3>GBR</s3><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Department of Cardiology, Castlehill Hospital, University of Hull, Kingston upon Hull</wicri:noRegion></affiliation></author><author><name sortKey="Cotter, Gadi" sort="Cotter, Gadi" uniqKey="Cotter G" first="Gadi" last="Cotter">Gadi Cotter</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Departmentof Medicine, Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Durham, NC</wicri:noRegion></affiliation></author><author><name sortKey="Jondeau, Guillaume" sort="Jondeau, Guillaume" uniqKey="Jondeau G" first="Guillaume" last="Jondeau">Guillaume Jondeau</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Cardiology, Hôpital Ambroise Paré</s1><s2>Boulogne</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Boulogne</wicri:noRegion><wicri:noRegion>Hôpital Ambroise Paré</wicri:noRegion><wicri:noRegion>Boulogne</wicri:noRegion></affiliation></author><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Departments of Medicine, Epidemiology and Preventive Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>7 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Melbourne, Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Metra, Marco" sort="Metra, Marco" uniqKey="Metra M" first="Marco" last="Metra">Marco Metra</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Cardiology, University of Brescia</s1><s2>Brescia</s2><s3>ITA</s3><sZ>8 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Brescia</wicri:noRegion></affiliation></author><author><name sortKey="O Connor, Christopher M" sort="O Connor, Christopher M" uniqKey="O Connor C" first="Christopher M." last="O'Connor">Christopher M. O'Connor</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Departmentof Medicine, Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Durham, NC</wicri:noRegion></affiliation></author><author><name sortKey="Parker, John D" sort="Parker, John D" uniqKey="Parker J" first="John D." last="Parker">John D. Parker</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Mount Sinai and United Health Network Hospitals</s1><s2>Toronto</s2><s3>CAN</s3><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Mount Sinai and United Health Network Hospitals</wicri:noRegion></affiliation></author><author><name sortKey="Torre Amione, Guillermo" sort="Torre Amione, Guillermo" uniqKey="Torre Amione G" first="Guillermo" last="Torre-Amione">Guillermo Torre-Amione</name><affiliation wicri:level="4"><inist:fA14 i1="10"><s1>Methodist DeBakey Heart Center, The Winter's Center for Heart Failure Research, Baylor College of Medicine</s1><s2>Houston, Tex</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Cardiology, Thorax Center, University Hospital Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>12 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Frey, Aline" sort="Frey, Aline" uniqKey="Frey A" first="Aline" last="Frey">Aline Frey</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Actelion Pharmaceuticals, Ltd</s1><s2>Allschwil</s2><s3>CHE</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Allschwil</wicri:noRegion></affiliation></author><author><name sortKey="Rainisio, Maurizio" sort="Rainisio, Maurizio" uniqKey="Rainisio M" first="Maurizio" last="Rainisio">Maurizio Rainisio</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Actelion Pharmaceuticals, Ltd</s1><s2>Allschwil</s2><s3>CHE</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Allschwil</wicri:noRegion></affiliation></author><author><name sortKey="Kobrin, Isaac" sort="Kobrin, Isaac" uniqKey="Kobrin I" first="Isaac" last="Kobrin">Isaac Kobrin</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Actelion Pharmaceuticals, Ltd</s1><s2>Allschwil</s2><s3>CHE</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Allschwil</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">The American heart journal</title><title level="j" type="abbreviated">Am. heart j.</title><idno type="ISSN">0002-8703</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The American heart journal</title><title level="j" type="abbreviated">Am. heart j.</title><idno type="ISSN">0002-8703</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute</term><term>Biological receptor</term><term>Cardiology</term><term>Circulatory system</term><term>Design</term><term>Endothelin</term><term>Heart failure</term><term>Human</term><term>Inhibition</term><term>Phlebology</term><term>Tezosentan</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Insuffisance cardiaque</term><term>Tézosentan</term><term>Homme</term><term>Aigu</term><term>Conception</term><term>Endothéline</term><term>Récepteur biologique</term><term>Inhibition</term><term>Appareil circulatoire</term><term>Cardiologie</term><term>Phlébologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background Endothelin 1 is a potent endogenous vasoconstrictor neurohormone, and endothelin 1 plasma concentrations predict adverse outcomes in patients with acute heart failure (AHF). Tezosentan, an intravenous endothelin receptor antagonist, improved hemodynamics in patients with AHF; however, its effects on morbidity and mortality have not been evaluated. Methods The VERITAS program consists of 2 identical, double-blind, randomized, placebo-controlled, concurrently conducted trials (VERITAS-1 and VERITAS-2), performed in 150 centers in Europe, Israel, Australia, and North America. The program is designed to enroll at least 1760 patients hospitalized with dyspnea at rest because of AHF requiring intravenous therapy. In addition to conventional therapy, patients are randomized to receive tezosentan (5 mg/h for 30 minutes, then 1 mg/h for 24-72 hours) or matching placebo. The 2 prespecified primary end points are the incidence of death or worsening heart failure at 7 days in the combined studies and the change from baseline in dyspnea over the first 24 hours of treatment, measured using a visual analog scale in VERITAS-1 and VERITAS-2, individually. Results Enrollment started in April 2003, and the program was discontinued in November 2005 because of the low probability of achieving a significant treatment effect. Conclusions No currently available agents have been shown in a prospective, randomized, clinical trial to improve outcomes in patients with AHF. Thus, the VERITAS program will provide valuable insights into the effect of tezosentan on clinical outcomes in patients with AHF, as well as hemodynamics and clinical symptoms.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0002-8703</s0></fA01><fA02 i1="01"><s0>AHJOA2</s0></fA02><fA03 i2="1"><s0>Am. heart j.</s0></fA03><fA05><s2>150</s2></fA05><fA06><s2>1</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Tezosentan in patients with acute heart failure : Design of the value of endothelin receptor inhibition with tezosentan in acute heart failure study (VERITAS)</s1></fA08><fA11 i1="01" i2="1"><s1>TEERLINK (John R.)</s1></fA11><fA11 i1="02" i2="1"><s1>MCMURRAY (John J. V.)</s1></fA11><fA11 i1="03" i2="1"><s1>BOURGE (Robert C.)</s1></fA11><fA11 i1="04" i2="1"><s1>CLELAND (John G. F.)</s1></fA11><fA11 i1="05" i2="1"><s1>COTTER (Gadi)</s1></fA11><fA11 i1="06" i2="1"><s1>JONDEAU (Guillaume)</s1></fA11><fA11 i1="07" i2="1"><s1>KRUM (Henry)</s1></fA11><fA11 i1="08" i2="1"><s1>METRA (Marco)</s1></fA11><fA11 i1="09" i2="1"><s1>O'CONNOR (Christopher M.)</s1></fA11><fA11 i1="10" i2="1"><s1>PARKER (John D.)</s1></fA11><fA11 i1="11" i2="1"><s1>TORRE-AMIONE (Guillermo)</s1></fA11><fA11 i1="12" i2="1"><s1>VAN VELDHUISEN (Dirk J.)</s1></fA11><fA11 i1="13" i2="1"><s1>FREY (Aline)</s1></fA11><fA11 i1="14" i2="1"><s1>RAINISIO (Maurizio)</s1></fA11><fA11 i1="15" i2="1"><s1>KOBRIN (Isaac)</s1></fA11><fA14 i1="01"><s1>Section of Cardiology, San Francisco Veterans Affairs Medical Center and University of California, San Francisco</s1><s2>San Francisco, Calif</s2><s3>USA</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Medicine and Therapeutics, University of Glasgow</s1><s2>Glasgow</s2><s3>GBR</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Medicine, University of Alabama at Birmingham</s1><s2>Birmingham, Ala</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Cardiology, Castlehill Hospital, University of Hull, Kingston upon Hull</s1><s3>GBR</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Departmentof Medicine, Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute</s1><s2>Durham, NC</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>9 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Cardiology, Hôpital Ambroise Paré</s1><s2>Boulogne</s2><s3>FRA</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>Departments of Medicine, Epidemiology and Preventive Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>Department of Cardiology, University of Brescia</s1><s2>Brescia</s2><s3>ITA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="09"><s1>Mount Sinai and United Health Network Hospitals</s1><s2>Toronto</s2><s3>CAN</s3><sZ>10 aut.</sZ></fA14><fA14 i1="10"><s1>Methodist DeBakey Heart Center, The Winter's Center for Heart Failure Research, Baylor College of Medicine</s1><s2>Houston, Tex</s2><s3>USA</s3><sZ>11 aut.</sZ></fA14><fA14 i1="11"><s1>Department of Cardiology, Thorax Center, University Hospital Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>12 aut.</sZ></fA14><fA14 i1="12"><s1>Actelion Pharmaceuticals, Ltd</s1><s2>Allschwil</s2><s3>CHE</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ><sZ>15 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>VERITAS Investigators</s1><s3>INC</s3></fA17><fA20><s1>46-53</s1></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>2057</s2><s5>354000131574590090</s5></fA43><fA44><s0>0000</s0><s1>© 2005 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>45 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>05-0391874</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>The American heart journal</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Background Endothelin 1 is a potent endogenous vasoconstrictor neurohormone, and endothelin 1 plasma concentrations predict adverse outcomes in patients with acute heart failure (AHF). Tezosentan, an intravenous endothelin receptor antagonist, improved hemodynamics in patients with AHF; however, its effects on morbidity and mortality have not been evaluated. Methods The VERITAS program consists of 2 identical, double-blind, randomized, placebo-controlled, concurrently conducted trials (VERITAS-1 and VERITAS-2), performed in 150 centers in Europe, Israel, Australia, and North America. The program is designed to enroll at least 1760 patients hospitalized with dyspnea at rest because of AHF requiring intravenous therapy. In addition to conventional therapy, patients are randomized to receive tezosentan (5 mg/h for 30 minutes, then 1 mg/h for 24-72 hours) or matching placebo. The 2 prespecified primary end points are the incidence of death or worsening heart failure at 7 days in the combined studies and the change from baseline in dyspnea over the first 24 hours of treatment, measured using a visual analog scale in VERITAS-1 and VERITAS-2, individually. Results Enrollment started in April 2003, and the program was discontinued in November 2005 because of the low probability of achieving a significant treatment effect. Conclusions No currently available agents have been shown in a prospective, randomized, clinical trial to improve outcomes in patients with AHF. Thus, the VERITAS program will provide valuable insights into the effect of tezosentan on clinical outcomes in patients with AHF, as well as hemodynamics and clinical symptoms.</s0></fC01><fC02 i1="01" i2="X"><s0>002B12A01</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Insuffisance cardiaque</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Heart failure</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Insuficiencia cardíaca</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Tézosentan</s0><s2>NK</s2><s2>FR</s2><s5>05</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Tezosentan</s0><s2>NK</s2><s2>FR</s2><s5>05</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Tezosentán</s0><s2>NK</s2><s2>FR</s2><s5>05</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Human</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Aigu</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Acute</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Agudo</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Conception</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Design</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Diseño</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Endothéline</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Endothelin</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Endothelina</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Récepteur biologique</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Biological receptor</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Receptor biológico</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Inhibition</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Inhibition</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Inhibición</s0><s5>14</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Appareil circulatoire</s0><s5>15</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Circulatory system</s0><s5>15</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Aparato circulatorio</s0><s5>15</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Cardiologie</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Cardiology</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Cardiología</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Phlébologie</s0><s5>18</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Phlebology</s0><s5>18</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Flebología</s0><s5>18</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Cardiopathie</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Heart disease</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Cardiopatía</s0><s5>38</s5></fC07><fN21><s1>276</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Australie</li><li>Canada</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country><region><li>Californie</li><li>Groningue (province)</li><li>Texas</li><li>Écosse</li></region><settlement><li>Glasgow</li><li>Groningue</li><li>Houston</li><li>San Francisco</li></settlement><orgName><li>Baylor College of Medicine</li><li>Université de Glasgow</li></orgName></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Teerlink, John R" sort="Teerlink, John R" uniqKey="Teerlink J" first="John R." last="Teerlink">John R. Teerlink</name></region><name sortKey="Bourge, Robert C" sort="Bourge, Robert C" uniqKey="Bourge R" first="Robert C." last="Bourge">Robert C. Bourge</name><name sortKey="Cotter, Gadi" sort="Cotter, Gadi" uniqKey="Cotter G" first="Gadi" last="Cotter">Gadi Cotter</name><name sortKey="O Connor, Christopher M" sort="O Connor, Christopher M" uniqKey="O Connor C" first="Christopher M." last="O'Connor">Christopher M. O'Connor</name><name sortKey="Torre Amione, Guillermo" sort="Torre Amione, Guillermo" uniqKey="Torre Amione G" first="Guillermo" last="Torre-Amione">Guillermo Torre-Amione</name></country><country name="Royaume-Uni"><region name="Écosse"><name sortKey="Mcmurray, John J V" sort="Mcmurray, John J V" uniqKey="Mcmurray J" first="John J. V." last="Mcmurray">John J. V. Mcmurray</name></region><name sortKey="Cleland, John G F" sort="Cleland, John G F" uniqKey="Cleland J" first="John G. F." last="Cleland">John G. F. Cleland</name></country><country name="France"><noRegion><name sortKey="Jondeau, Guillaume" sort="Jondeau, Guillaume" uniqKey="Jondeau G" first="Guillaume" last="Jondeau">Guillaume Jondeau</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Metra, Marco" sort="Metra, Marco" uniqKey="Metra M" first="Marco" last="Metra">Marco Metra</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Parker, John D" sort="Parker, John D" uniqKey="Parker J" first="John D." last="Parker">John D. Parker</name></noRegion></country><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name></region></country><country name="Suisse"><noRegion><name sortKey="Frey, Aline" sort="Frey, Aline" uniqKey="Frey A" first="Aline" last="Frey">Aline Frey</name></noRegion><name sortKey="Kobrin, Isaac" sort="Kobrin, Isaac" uniqKey="Kobrin I" first="Isaac" last="Kobrin">Isaac Kobrin</name><name sortKey="Rainisio, Maurizio" sort="Rainisio, Maurizio" uniqKey="Rainisio M" first="Maurizio" last="Rainisio">Maurizio Rainisio</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004346 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 004346 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:05-0391874
|texte= Tezosentan in patients with acute heart failure : Design of the value of endothelin receptor inhibition with tezosentan in acute heart failure study (VERITAS)
}}
| This area was generated with Dilib version V0.6.33. |  |